Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor prognosis. For the first time, we report the use of interleukin-2 to stimulate a graft-versus-leukemia effect and induce complete remission in a patient with BRCA2 Fanconi anemia and refractory acute myelogenous leukemia, suggesting the potential of immunotherapy in this setting. Interleukin-2 was associated with significant infusion-related toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0b013e31828e5c56 | DOI Listing |
Publication Analysis
Top Keywords
fanconi anemia
12
brca2 fanconi
8
interleukin-2-induced graft-versus-leukemia
4
graft-versus-leukemia treatment
4
treatment aml
4
aml brca2
4
anemia patient
4
patient biallelic
4
biallelic brca2
4
brca2 mutations
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!